Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma Who Have Received at Least 4 Prior Therapies Including an Immunomodulatory Drug, a Proteasome Inhibitor, and an Anti-CD38 Antibody

Next Previous
Trial Profile

A Phase 3 Study Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma Who Have Received at Least 4 Prior Therapies Including an Immunomodulatory Drug, a Proteasome Inhibitor, and an Anti-CD38 Antibody

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talquetamab (Primary) ; Belantamab mafodotin
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms MonumenTAL-5
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 16 Dec 2022 Status changed from recruiting to withdrawn prior to enrolment.
  • 13 Dec 2022 The study will open for enrollment in October 2022, as per trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 13 Dec 2022 Trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top